Integration of mental health services into primary care overcomes ethnic disparities in access to mental health services between black and white elderly

American Journal of Geriatric Psychiatry

Volumn 15, Issue 10, 2007, Pages 906-912

  Ayalon, Liat ^a   Areán, Patricia A ^b   Linkins, Karen ^d,e   Lynch, Marty ^f   Estes, Carroll L ^c  

^a BAR ILAN UNIVERSITY   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Institute for Health and Aging   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LEWIN GROUP   (United States)

^f Lifelong Medical Care   (United States)

Author keywords

access to care; disparity; ethnic minorities; Mental health services

Indexed keywords

AFRICAN AMERICAN; AGED; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRINKING BEHAVIOR; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; GERIATRIC PATIENT; HAZARD RATIO; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HUMAN; MALE; MENTAL HEALTH; MENTAL HEALTH CENTER; MENTAL HEALTH SERVICE; MULTICENTER STUDY; PATIENT REFERRAL; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE ABUSE; CAUCASIAN; COMPARATIVE STUDY; EDUCATIONAL STATUS; ETHNOLOGY; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH STATUS; MENTAL DISEASE; METHODOLOGY; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; PRIMARY HEALTH CARE; PSYCHOLOGICAL ASPECT; SEX DIFFERENCE; STANDARD; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

AFRICAN AMERICANS; AGED; CALIFORNIA; DELIVERY OF HEALTH CARE; EDUCATIONAL STATUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH FACILITY MERGER; HEALTH STATUS; HUMANS; MALE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; MODELS, ORGANIZATIONAL; PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION; SEX FACTORS;

EID: 38449115419     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e318135113e     Document Type: Article

References (65)

1. Bartus RT, Dean RL, Beer B et al: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408-414
2. Cummings JL: The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease. Int J Neuropsychopharmacol 2000; 3:21-29
3. Greenamyre JT: The role of glutamate in neurotransmission and in neurologic disease. Arch Neurol 1986; 43:1058-1063
4. Maragos WF, Greenmyre JT, Penney JB, et al: Glutamate dysfunction in Alzheimer's disease: An hypothesis. Trends Neurosci 1987; 10:65-68
5. Mega MS, Masterman DM, O'Connor SM, et al: The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999; 56:1388-1393
6. Lanctôt KL, Herrmann N, Yau KK, et al: Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003; 169:557-564
7. Areosa SA, Sherriff F: Memantine for dementia. Cochrane Database Syst Rev. 2003:CD003154
8. Herrmann N, Lanctôt KL: From transmitters to treatment: The pharmacotherapy of behavioral disturbances in dementia. Can J Psychiatry 1997; 42:51S-64S
9. Lanctôt KL, Herrmann N, Mazzotta P: Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2001; 13:5-21
10. Hall H, Lundkvist C, Halldin C, et al: Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635. Brain Res 1997; 745:96-108
11. Barnes NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38:1083-1152
12. Sumiyoshi T, Matsui M, Yamashita I, et al: The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 2001; 49:861-868
13. Schechter LE, Dawson LA, Harder JA: The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease. Curr Pharm Des 2002; 8:139-145
14. Huang YY, Battistuzzi C, Oquendo MA, et al: Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol 2004; 7:441-451
15. Tauscher J, Kapur S, Verhoeff NP, et al: Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 2002; 59:514-520
16. Fuller RW: Role of serotonin in therapy of depression and related disorders. J Clin Psychiatry 1991; 52Suppl:52-57
17. Lesch KP, Gutknecht L: Focus on The 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics. Int J Neuropsychopharmacol 2004; 7:381-385
18. Lai MK, Tsang SW, Francis PT, et al: Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res 2003; 974:82-87
19. Haddjeri N, Lucas G, Blier P: Role of cholinergic and GABAergic systems in the feedback inhibition of dorsal raphe 5-HT neurons. Neuroreport 2000; 11:3397-3401
20. Haddjeri N, Faure C, Lucas G, et al: In-vivo modulation of central 5-hydroxytryptamine (5-HT1A) receptor-mediated responses by the cholinergic system. Int J Neuropsychopharmacol 2004: 1-9
21. Middlemiss DN, Palmer AM, Edel N, et al: Binding of the novel serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin in normal and Alzheimer brain. J Neurochem 1986; 46:993-996
22. Proctor AW, Middlemiss DN, Bowen DM: Selective loss of serotonin recognition sites in the parietal cortex in Alzheimer's disease. Int J Geriat Psychiatry 1988; 3:37-44
23. Bowen DM, Allen SJ, Benton JS, et al: Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem 1983; 41:266-272
24. Bowen DM, Najlerahim A, Procter AW, et al: Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc Natl Acad Sci U S A 1989; 86:9504-9508
25. Cross AJ, Slater P, Perry EK, et al: An autoradiographic analysis of serotonin receptors in human temporal cortex: changes in Alzheimer-type dementia. Neurochm Int 1988; 13:89-96
26. Crow TJ, Cross AJ, Cooper SJ, et al: Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 1984; 23:1561-1569
27. Palmer AM, Francis PT, Benton JS, et al: Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem 1987; 48:8-15
28. Burnet PW, Eastwood SL, Harrison PJ: [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 1997; 30:565-574
29. Fletcher A, Cliffe IA, Dourish CT: Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. Trends Pharmacol Sci 1993; 14:41-48
30. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
31. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC, American Psychiatric Association, 1994
32. Reisberg B, Ferris SH, deLeon MJ, et al: The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139:1136-1139
33. Folstein MF, Folstein SE: "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12:189-198
34. Hachinski VC, Iliff LD, Zilhka E, et al: Cerebral blood flow in dementia. Arch Neurol 1975; 32:632-637
35. Alexopoulos GS, Abrams RC, Young RC, et al: Cornell Scale for Depression in Dementia. Biol Psychiatry 1988; 23:271-284
36. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314
37. Mattis S: Mental status examination for organic mental syndrome in the elderly patient, in geriatric psychiatry: a handbook for psychiatrists and primary care physicians. Edited by Bellak L, Karasu T. New York, Grune & Stratton, 1976: pp 77-101
38. Crum RM, Anthony JC, Bassett SS, et al: Population-based norms for the Mini-Mental State Examination by age and educational level. Jama 1993; 269:2386-2391
39. Yesavage JA, Brink TL, Rose TL, et al: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982; 17:37-49
40. 1A receptor radioligand, [carbonyl-C-11]WAY-100635, via C-11- carboxylation of an immobilized Grignard reagent. J Labelled Comp Radiopharm 1996; 38:941-953
41. Tauscher J, Verhoeff NP, Christensen BK, et al: Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C]WAY-100635 and PET. Neuropsychopharmacology 2001; 24:522-530
42. Studholme C, Hill DLG, Hawkes DJ: An overlap invariant entropy measure of 3D medical image alignment. Pattern Recognition 1999; 32:71-86
43. Talairach J, Tournoux P: Co-planar stereotaxic atlas of the human brain. 3-Dimensional proportional system: an approach to cerebral imaging. New York, Thieme Medical, 1988
44. Bremner JD, Bronen RA, De Erasquin G, et al: Development and reliability of a method for using magnetic resonance imaging for the definition of regions of interest for positron emission tomography. Clin Pos Imag 1998; 1:145-159
45. Lammertsma A, Hume S: Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4:153-156
46. Gunn RN, Sargent PA, Bench CJ, et al: Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-C-11]WAY-100635 for PET. Neuroimage 1998; 8:426-440
47. Muller-Gartner HW, Links JM, Prince JL, et al: Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992; 12:571-583
48. Bencherif B, Stumpf MJ, Links JM, et al: Application of MRI-based partial-volume correction to the analysis of PET images of μ-opioid receptors using statistical parametric mapping. J Nucl Med 2004; 45:402-408
49. Evans AC, Thompson CJ, Marrett S, et al: Performance evaluation of the PC-2048: a new 15-slice encoded-crystal PET scanner for neurological studies. IEEE Transactions on Medical Imaging 1991; 10:90-98
50. Rousset O, Ma Y, Kamber M, et al: 3D simulations of radiotracer uptake in deep nuclei of human brain. Comput Med Imaging Graph 1993; 17:373-379
51. Friston KJ, Holmes AP, Worsley KL: Statitiscal parametric maps in functional imaging: a general linear approach. Human Brain Mapping 1995; 2:189-210
52. Meltzer CC, Price JC, Mathis CA, et al: PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry 1999; 156:1871-1878
53. Meltzer CC, Smith G, Price JC, et al: Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res 1998; 813:167-171
54. Giovacchini G, Toczek MT, Bonwetsch R, et al: 5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. J Nucl Med 2005; 46:1128-1135
55. Matsuda H, Kitayama N, Ohnishi T, et al: Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer's disease. J Nucl Med 2002; 43:304-311
56. Cross AJ, Crow TJ, Ferrier IN, et al: Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem 1984; 43:1574-1581
57. Jobst KA, Smith AD, Szatmari M, et al: Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet 1994; 343:829-830
58. Dickerson BC, Salat DH, Bates JF, et al: Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004; 56:27-35
59. Yasuno F, Suhara T, Nakayama T, et al: Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. Am J Psychiatry 2003; 160:334-340
60. Newman-Tancredi A, Verriele L, Touzard M, et al: Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation. Eur J Pharmacol 2001; 428:177-184
61. Millan MJ: Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 2000; 295:853-861
62. Blier P, Abbott FV: Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 2001; 26:37-43
63. Harder JA, Maclean CJ, Alder JT, et al: The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. Psychopharmacology (Berl) 1996; 127:245-254
64. Harder JA, Ridley RM: The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology 2000; 39:547-552
65. Nordberg A: Neuroreceptor changes in Alzheimer disease. Cerebrovasc Brain Metab Rev 1992; 4:303-328